$3.50
1.69% day before yesterday
Nasdaq, May 02, 10:05 pm CET
ISIN
US8808811074
Symbol
TERN
Sector
Industry

Terns Pharmaceuticals Inc Stock price

$3.50
+1.01 40.56% 1M
-3.60 50.70% 6M
-2.04 36.82% YTD
-1.79 33.84% 1Y
+1.84 110.84% 3Y
-13.50 79.41% 5Y
-13.50 79.41% 10Y
Nasdaq, Closing price Fri, May 02 2025
-0.06 1.69%
ISIN
US8808811074
Symbol
TERN
Sector
Industry

Key metrics

Market capitalization $305.54m
Enterprise Value $-51.27m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.73
P/B ratio (TTM) P/B ratio 0.88
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-101.87m
Free Cash Flow (TTM) Free Cash Flow $-70.45m
Cash position $358.16m
EPS (TTM) EPS $-1.13
P/E forward negative
Short interest 7.00%
Show more

Is Terns Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,786 stocks worldwide.

Terns Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Terns Pharmaceuticals Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Terns Pharmaceuticals Inc forecast:

Buy
75%
Hold
25%

Financial data from Terns Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.90 0.90
2% 2%
-
-0.90 -0.90
2% 2%
-
- Selling and Administrative Expenses 30 30
20% 20%
-
- Research and Development Expense 70 70
10% 10%
-
-101 -101
1% 1%
-
- Depreciation and Amortization 0.90 0.90
2% 2%
-
EBIT (Operating Income) EBIT -102 -102
1% 1%
-
Net Profit -89 -89
2% 2%
-

In millions USD.

Don't miss a Thing! We will send you all news about Terns Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Terns Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
2 days ago
FOSTER CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2025 equity inducement awards to two new employees under th...
Neutral
GlobeNewsWire
4 days ago
FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens...
Neutral
GlobeNewsWire
about one month ago
FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees un...
More Terns Pharmaceuticals Inc News

Company Profile

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Head office United States
CEO Amy Burroughs
Employees 59
Founded 2017
Website www.ternspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today